Medical/Pharmaceuticals
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
Additions to executive team strengthen global leadership and position Company for strategic long-term growth First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 inChina advances Brii Bio from clinical development to commercial stage biotechnology co...
Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment
MELBOURNE, Australia and NANTES, France, Aug. 24, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. ('ATONCO') today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive...
Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals
LISBON, Portugal, Aug. 23, 2022 /PRNewswire/ -- Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor...
GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program
NANJING, China, Aug. 23, 2022 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announces FDA clearance of its IND application for innovative antibody drug program (SLC-3010). GenScript ProBio was responsible for the CMC development and supporting IND filing in this project. Gen...
Announcement of 2022 Future Science Prize Winners: Wenhui Li, Xueming Yang, Ngaiming Mok
BEIJING, Aug. 23, 2022 /PRNewswire/ -- The Future Science Prize committee announces the winners of 2022 onAugust 21st. Prof. Wenhui Li from National Institute of Biological Sciences,Beijing, China; Tsinghua Institute of Multidisciplinary Biomedical Research receives the Future Science Prize in li...
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
Building a leadership team with global and local experience and expertise to
enable rapid execution across Company's broad therapeutic strategy
DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences
Australians Takes Part in World Blood Donation Record Attempt to Save Lives
Global campaign to save 150,000 lives through 50,000 donations around the world.
SYDNEY, Aug. 23, 2022 /PRNewswire/ -- On Saturday 27 August, Australians will
attempt to break the world record for the most blood donations in one calendar
day.
DxGen Corp. and Precision Diabetes, Inc. Announce Strategic Partnership to Launch New Diabetes Point-Of-Care Testing Analyzer into the U.S. Market.
RALEIGH, N.C. and SEOUL, Korea, Aug. 22, 2022 /PRNewswire/ -- Precision Diabetes, Inc. and DxGen Corp. are pleased to announce that they have entered in an exclusive agreement in the U.S. to launch Epithod® AutoDx, a fully-automatic point-of-care (POC) analyzer that measures a comprehensive prof...
Prominent ophthalmologist will guide Turn Bio's search for therapies to cure eye diseases
Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA ...
LTS takes next step in its Growth Journey with the acquisition of Tapemark Inc.
ANDERNACH, Germany, Aug. 22, 2022 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS") announces the closing of the acquisition of Tapemark Inc. ("Tapemark") located inSt. Paul, MN, USA. This acquisition combines Tapemark, a world-class CDMO specialized in transdermal drug delivery systems and...
The 2022 Smart China Expo kicked off, smart technology empowers Chongqing Liangjiang New Area to lead innovative development
CHONGQING, China, Aug. 22, 2022 /PRNewswire/ -- The 2022 Smart China Expo will be held in Liangjiang New Area of southwest China'sChongqing from August 22 to 24, with the theme of "Smart Technology: Empowering Economy, Enriching Life". As the most influential event in China's intelligent industry...
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can beginonce a policy recommendation from the CDC is received GAITHERSBURG, Md., Aug. 2...
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes
HONG KONG, Aug. 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has been selected as a constituent stock of eight index series including...
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
-- Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a new and differentiated chemical...
Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
* Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union * Submission supported by results from the pivo...
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Compa...
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment and dosing for the comparative Phase II clinical trial between its recombina...
Ping An Health posts revenue of RMB2,828 million in the first half of 2022
Gross margin improves to 27.3% Cumulative paying users reaches over 40 million HONG KONG and SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or "Ping An Health"; Stock Code: 1833.HK), announced its 2022 interim results. Since the de...
Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched inChina, 1 in ...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 287 media titles]
2024-04-30 10:11INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00